Kinnate Biopharma Inc., a biopharmaceutical company, focuses on the discovery and development of small molecule kinase inhibitors to treat genomically defined cancers in the United States. The company develops KIN-2787, a rapidly accelerated fibrosarcoma inhibitor for the treatment of patients with lung cancer, melanoma, and other solid tumors; KIN-3248 small-molecule kinase inhibitors that target cancer-associated alterations in fibroblast growth factor receptors FGFR2 and FGFR3 genes; and small molecule research programs, including Cyclin-Dependent Kinase 12(CDK12) inhibitor in its KIN004 program. The company was incorporated in 2018 and is headquartered in San Francisco, California. Kinnate Biopharma Inc. is a former subsidiary of Fount Therapeutics, LLC.
Kinnate Biopharma Inc. (KNTE) - Company Outlook
Company Outlook
| Year | Receivables | Debt | Liabilities | Assets | Current Assets |
|---|---|---|---|---|---|
| 2023 | -53,823,000 | 14.28 M | 173.61 M | 158.18 M | |
| 2022 | -25,079,000 | 20.36 M | 278.83 M | 230.84 M | |
| 2021 | -116,096,000 | 12.39 M | 366.86 M | 258.69 M | |
| 2020 | -365,462,000 | 7.3 M | 400.57 M | 400.2 M | |
| 2019 | 973 K | -76,453,000 | 95.09 M | 77.61 M | 77.45 M |